BR0313384A - Derivados de cromona como inibidores de metaloproteinases de matriz - Google Patents
Derivados de cromona como inibidores de metaloproteinases de matrizInfo
- Publication number
- BR0313384A BR0313384A BR0313384-2A BR0313384A BR0313384A BR 0313384 A BR0313384 A BR 0313384A BR 0313384 A BR0313384 A BR 0313384A BR 0313384 A BR0313384 A BR 0313384A
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutically acceptable
- formula
- acceptable salt
- compound
- disease
- Prior art date
Links
- 150000004777 chromones Chemical class 0.000 title 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 title 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 150000003839 salts Chemical class 0.000 abstract 6
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 102000004190 Enzymes Human genes 0.000 abstract 2
- 108090000790 Enzymes Proteins 0.000 abstract 2
- 206010019280 Heart failures Diseases 0.000 abstract 2
- 201000008482 osteoarthritis Diseases 0.000 abstract 2
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical class C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000000414 obstructive effect Effects 0.000 abstract 1
- 208000028169 periodontal disease Diseases 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
- C07D265/22—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrane Compounds (AREA)
Abstract
"DERIVADOS DE CROMONA COMO INIBIDORES DE METALOPROTEINASES DE MATRIZ". A presente invenção refere-se a compostos definidos pela Fórmula I ou um seu sal farmaceuticamente aceitável, em que R^ 1~, Q, Y^ 2^, Y^ 3^, Y^ 4^, U^ 5^, U^ 6^, U^ 8^, e R^ 2^ são como definidos na especificação. A invenção também proporciona composições farmacêuticas que compreendem um composto de Fórmula I, ou um seu sal farmaceuticamente aceitável, como definido na especificação, conjuntamente com um veículo 10 diluente ou excipiente farmaceuticamente aceitável. A invenção também proporciona métodos de inibição de uma enzima de MW-13 em um animal, que compreende a administração ao animal de um composto de Fórmula I, ou um seu sal farmaceuticamente aceitável. A invenção também proporciona métodos de tratamento de uma doença mediada por uma enzima de MNIP-13 em um paciente, que compreende a administração ao paciente de um composto de fórmula I, ou um seu sal farmaceuticamente aceitável, quer sozinho ou em uma composição farmacêutica. A invenção também proporciona métodos de tratamento de doenças tais como doença cardíaca, esclerose múltipla, osteoartrite e artrite reumatóide, artrite que não osteoartrite ou artrite reumatóide, insuficiência cardíaca, doença inflamatória do intestino, insuficiência cardíaca, degeneração macular relacionada com a idade, doença pulmonar obstrutiva crónica, asma, doenças periodontais, psoríase, aterosclerose, e osteoporose em um paciente que compreende a administração ao paciente de um composto de Fórmula I, ou de um seu sal farmaceuticamente aceitável, quer sozinho ou em uma composição farmacêutica. A invenção também proporciona combinações, que compreendem um composto de Fórmula I, ou um seu sal farmaceuticamente aceitável, conjuntamente com outro componente farmaceuticamente ativo como descrito na especificação.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40309402P | 2002-08-13 | 2002-08-13 | |
| PCT/IB2003/003541 WO2004014880A1 (en) | 2002-08-13 | 2003-08-04 | Chromone derivatives as matrix metalloproteinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0313384A true BR0313384A (pt) | 2005-07-12 |
Family
ID=31715935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0313384-2A BR0313384A (pt) | 2002-08-13 | 2003-08-04 | Derivados de cromona como inibidores de metaloproteinases de matriz |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6908917B2 (pt) |
| EP (1) | EP1537090A1 (pt) |
| JP (1) | JP2005539020A (pt) |
| AU (1) | AU2003253150A1 (pt) |
| BR (1) | BR0313384A (pt) |
| CA (1) | CA2497658A1 (pt) |
| MX (1) | MXPA05001785A (pt) |
| WO (1) | WO2004014880A1 (pt) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8539401A1 (es) * | 2001-02-14 | 2002-10-28 | Warner Lambert Co | Quinazolinas como inhibidores de mmp-13 |
| US6894057B2 (en) | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
| PA8578101A1 (es) * | 2002-08-13 | 2004-05-07 | Warner Lambert Co | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz |
| US20040142950A1 (en) * | 2003-01-17 | 2004-07-22 | Bunker Amy Mae | Amide and ester matrix metalloproteinase inhibitors |
| WO2005002585A1 (en) * | 2003-07-02 | 2005-01-13 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor |
| WO2005016926A1 (en) * | 2003-08-19 | 2005-02-24 | Warner-Lambert Company Llc | Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors |
| US20060247231A1 (en) * | 2003-12-18 | 2006-11-02 | Warner-Lambert Company Llc | Amide and ester matrix metalloproteinase inhibitors |
| USRE46558E1 (en) | 2005-04-28 | 2017-09-26 | Paloma Pharmaceuticals, Inc. | Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis |
| EP1996021B1 (en) * | 2006-02-28 | 2017-12-13 | Paloma Pharmaceuticals, Inc. | Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis |
| BRPI0909374A2 (pt) * | 2008-03-25 | 2015-10-06 | Paloma Pharmaceuticals Inc | métodos para tratar desordens fibróticas |
| LT2464645T (lt) | 2009-07-27 | 2017-10-25 | Gilead Sciences, Inc. | Kondensuoti heterocikliniai junginiai, kaip jonų kanalų moduliatoriai |
| US8703759B2 (en) | 2010-07-02 | 2014-04-22 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| WO2012052451A1 (en) | 2010-10-18 | 2012-04-26 | Merz Pharma Gmbh & Co. Kgaa | Metabotropic glutamate receptor modulators |
| US9381187B2 (en) | 2011-02-16 | 2016-07-05 | Paloma Pharmaceuticals, Inc. | Radiation countermeasure agents |
| KR20140033377A (ko) * | 2011-05-10 | 2014-03-18 | 길리애드 사이언시즈, 인코포레이티드 | 나트륨 채널 조절제로서의 융합된 헤테로시클릭 화합물 |
| NO3175985T3 (pt) | 2011-07-01 | 2018-04-28 | ||
| UY34171A (es) | 2011-07-01 | 2013-01-31 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como moduladores del canal iónico |
| WO2013019682A1 (en) * | 2011-07-29 | 2013-02-07 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
| CN103083313B (zh) * | 2013-01-17 | 2015-08-26 | 中山大学 | 一种取代吡咯色原酮类化合物在制备治疗5型磷酸二酯酶相关疾病的药物中的应用 |
| CN107865864A (zh) * | 2016-09-27 | 2018-04-03 | 全椒先奇医药科技有限公司 | Fistulains B在治疗或预防慢性心衰药物中的应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU717570B2 (en) * | 1995-06-02 | 2000-03-30 | Warner-Lambert Company | Tricyclic inhibitors of matrix metalloproteinases |
| CA2182932A1 (en) * | 1995-08-10 | 1997-02-11 | Koju Watanabe | Chromone derivative, process for preparing same and pharmaceutical composition |
| JP2000500739A (ja) * | 1995-10-13 | 2000-01-25 | アグレボ・ユー・ケイ・リミテツド | 複素環式殺菌剤 |
| US6008243A (en) | 1996-10-24 | 1999-12-28 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use |
| JPH11199512A (ja) | 1997-10-24 | 1999-07-27 | Pfizer Prod Inc | 変形性関節症および他のｍｍｐ媒介疾患の治療のためのｍｍｐ−１３選択的阻害剤の使用 |
| UA59453C2 (uk) | 1998-08-12 | 2003-09-15 | Пфайзер Продактс Інк. | Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ |
| HN2000000137A (es) | 1999-08-12 | 2001-02-02 | Pfizer Prod Inc | Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas |
| US6934639B1 (en) | 2000-02-25 | 2005-08-23 | Wyeth | Methods for designing agents that interact with MMP-13 |
| EP1138680A1 (en) | 2000-03-29 | 2001-10-04 | Pfizer Products Inc. | Gem substituted sulfonyl hydroxamic acids as MMP inhibitors |
| MXPA03003735A (es) | 2000-10-26 | 2003-07-28 | Pfizer Prod Inc | Inhibidores de espiropirimidin-2,4,6-triona metaloproteinasas. |
| SK4872003A3 (en) | 2000-10-26 | 2004-08-03 | Pfizer Prod Inc | Metaloproteinase pyrimidine-2,4,6-trione inhibitors |
| DOP2002000332A (es) | 2001-02-14 | 2002-08-30 | Warner Lambert Co | Inhibidores de piridina de metaloproteinasas de la matriz |
| MXPA03004920A (es) | 2001-02-14 | 2003-09-05 | Warner Lambert Co | Pirimidinas inhibidoras de metaloproteinasas de matriz. |
| ATE280164T1 (de) * | 2001-02-14 | 2004-11-15 | Warner Lambert Co | Benzothiadiazine als matrix metallproteinase inhibitoren |
| PA8539501A1 (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Compuestos triazolo como inhibidores de mmp |
| EP1370562A1 (en) | 2001-02-14 | 2003-12-17 | Warner-Lambert Company LLC | Thieno[2,3-d]pyrimidindione derivatives as matrix metalloproteinase inhibitors |
| PA8539301A1 (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Inhibidores de la metaloproteinasa de la matriz |
| DOP2002000333A (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz |
| DOP2002000334A (es) | 2001-02-14 | 2002-08-30 | Warner Lambert Co | Pirimidinas biciclicas como inhibidores de metaloproteinasas de matriz |
| PA8539401A1 (es) | 2001-02-14 | 2002-10-28 | Warner Lambert Co | Quinazolinas como inhibidores de mmp-13 |
| US6924276B2 (en) | 2001-09-10 | 2005-08-02 | Warner-Lambert Company | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors |
| WO2003033477A1 (en) * | 2001-10-12 | 2003-04-24 | Warner-Lambert Company Llc | Alkynlated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitor |
| PA8556301A1 (es) * | 2001-10-12 | 2003-09-05 | Warner Lambert Co | Compuestos pirimidina de anillo fusionado alquinilado |
| US6962922B2 (en) | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
| WO2003032999A1 (en) | 2001-10-12 | 2003-04-24 | Warner-Lambert Company Llc | Alkyne matrix metalloproteinase inhibitors |
| US6894057B2 (en) | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
| AU2002249275A1 (en) | 2002-03-08 | 2003-09-22 | Warner-Lambert Company Llc | Oxo azabicyclic compounds |
| US6747147B2 (en) | 2002-03-08 | 2004-06-08 | Warner-Lambert Company | Oxo-azabicyclic compounds |
| AU2002333256A1 (en) | 2002-06-25 | 2004-01-06 | Warner-Lambert Company Llc | Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis |
| US20040006077A1 (en) | 2002-06-25 | 2004-01-08 | Bernard Gaudilliere | Thiazine and oxazine derivatives as MMP-13 inhibitors |
-
2003
- 2003-08-04 CA CA002497658A patent/CA2497658A1/en not_active Abandoned
- 2003-08-04 AU AU2003253150A patent/AU2003253150A1/en not_active Abandoned
- 2003-08-04 WO PCT/IB2003/003541 patent/WO2004014880A1/en not_active Ceased
- 2003-08-04 BR BR0313384-2A patent/BR0313384A/pt not_active IP Right Cessation
- 2003-08-04 JP JP2004527218A patent/JP2005539020A/ja active Pending
- 2003-08-04 MX MXPA05001785A patent/MXPA05001785A/es not_active Application Discontinuation
- 2003-08-04 EP EP03784406A patent/EP1537090A1/en not_active Withdrawn
- 2003-08-05 US US10/634,718 patent/US6908917B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20040038974A1 (en) | 2004-02-26 |
| EP1537090A1 (en) | 2005-06-08 |
| US6908917B2 (en) | 2005-06-21 |
| JP2005539020A (ja) | 2005-12-22 |
| AU2003253150A1 (en) | 2004-02-25 |
| CA2497658A1 (en) | 2004-02-19 |
| MXPA05001785A (es) | 2005-04-25 |
| WO2004014880A1 (en) | 2004-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0313460A (pt) | Derivados de naftaleno como inibidores de metaloproteinase da matriz | |
| BR0313384A (pt) | Derivados de cromona como inibidores de metaloproteinases de matriz | |
| BR0313459A (pt) | Derivados monocìclicos como inibidores de metaloproteinases de matriz | |
| BR0313464A (pt) | Derivados heterobiarilo como inibidores da metaloproteinase de matriz | |
| BR0313724A (pt) | Derivados de azaisoquinolina como inibidores de metaloproteinase de matriz | |
| BR0210711A (pt) | Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto | |
| BR9916732A (pt) | Derivados de ácido malÈnico, processo para a sua preparação, seu uso e composições farmacêuticas contendo-os (inibição da atividade do fator xa) | |
| BRPI0409314A (pt) | derivados de 2-aminopirimidina e seu uso médico | |
| BR0203644A (pt) | Derivados heteroarìlicos dissubstituìdos com ácido como inibidores de metaloproteinase de matriz | |
| BR122019010200B8 (pt) | compostos de pirazol-quinazolina, seus sais, produtos ou kits e composições farmacêuticas | |
| MA31685B1 (fr) | Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met | |
| EA200602191A1 (ru) | 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения | |
| BRPI0514448A (pt) | derivados do ácido bifenil-oxiacético para uso no tratamento de doenças respiratórias | |
| BR0316386A (pt) | Benzoxazin-3-onas e seus derivados como inibidores de p13k | |
| BR0313240A (pt) | Cicloalquenilaminas condensadas por heteroarila, acilas e seu uso como farmacêuticos | |
| EP1256588A4 (en) | NEW PYRAZINE DERIVATIVES OR SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING THE DERIVATIVES OR THEIR SALTS AND INTERMEDIATES FOR BOTH PRODUCTION | |
| NO20050134L (no) | Difenylazetidioner substituert med syregrupper, fremgangsmate for fremstilling av disse, medikamenter inneholdende disse forbindelser og deres anvendelse | |
| AR022423A1 (es) | Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento | |
| BRPI0719920B8 (pt) | derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo e composto intermediário | |
| ATE312815T1 (de) | Neue verbindungen | |
| BRPI0512252A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto combinado, e, processo para a preparação de um composto | |
| BR0317426A (pt) | Inibidores de proteìna de transferência de triglicéridos microssomais | |
| EP2077719A4 (en) | PIPERIDINE AND PYRROLIDIN BETA SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE | |
| BRPI0610205A2 (pt) | piperidinas 3,4-substituìdas como inibidores da renina | |
| BRPI0712312A2 (pt) | Composto, processo para a produção do mesmo, composição farmacêutica, agente antimicrobiano, agente anti-mrsa, método para a prevenção ou o tratamento de uma doença infecciosa, e, uso do composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 4A, 5A, 6A E 7A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2064 DE 27/07/2010. |